Canadian Benchmarking Study Focused on Multi-Employer and Target Benefit Pension Plans

Published By: PBI Actuarial Consultants | 29/01/2021

What are other pension plans doing that might also benefit your plan and its members? How do your plan’s contribution and benefit rates compare to others? What has been the effect of the COVID-19 pandemic on MEPP/TBP plans? Could you improve your pension plan’s risk efficiency? Find the answers to these questions and more in the 2021 Apples & Oranges Study.

Learn More

Recent Research Papers

View All Research Papers


  • Announcement: Sun Life Global Investments is pleased to announce the appointment of Satwik Misra, MBA, CFA®, as Director, Business Development and Client Relationships, Ontario....More Information
  • Announcement: iA Financial Group appoints a new Executive Vice-President for its group division Éric Jobin ...More Information
  • Announcement: T. Rowe Price, Inc., has hired Samantha Cleyn, CFA®, as Head of Eastern Canada, based in Montreal....More Information
  • Announcement: Tony Arrell, Robert Sankey, Richard Rooney and the partners of BURGUNDY ASSET MANAGEMENT LTD. are pleased to announce the following appointment...More Information
  • Announcement: Mawer Investment Management Ltd. is pleased to announce the addition of Anum Siddiqui and Neeraj Jain to the Institutional Client Management team...More Information
  • Announcement: Shoppers is pleased to announce Mike Smiley as Director Business Development for Western Canada...More Information
  • Announcement: Desjardins Insurance is pleased to announce the appointment of Amy Ferguson to the position of Regional Vice-President....More Information
  • Announcement: Guardian Capital LP Expanding Its Reach Appoints Sherry Lee Gregory, Vice President, Institutional Sales and Consultant Relations...More Information
  • View All

Have an Announcement
or Classified You'd Like To List?
Contact Us


Strategy Needed For High Cost Drugs

February 25, 2021

Drug plan managers have long struggled to address the management of high cost drugs which, on one hand, vastly improve claimants’ health outcomes and provide better quality of life, but, on the other hand, have an ever-expanding place in group health benefits’ budgets. In ‘Specialty Drug Strategy: How To Look Beyond The (High) Cost With A Five-Pillar Approach,’ Christine Than, a pharmacist and drug solution specialist at Aon, says while the use of specialty drugs, account for only for about one per cent of all drug claims, they represent approximately 35 per cent on average of total drug plan spend. When addressing specialty drug coverage, an employer’s drug cost containment strategy should be coherent with their total rewards strategy, she says.


Download PDF

Interested in Advertising on our Website or Magazine? Contact our Sales Team


10 Reasons to advertise with Benefits and Pensions Monitor   ...Play Video

Health by Design: William's struggle with depression   ...Play Video

Benefits and Pensions Monitor 30 second presentation in Canada   ...Play Video